GUILLAIN-BARRE SYNDROME

EU regulator reviews reports of rare nervous disorder after AstraZeneca vaccine

EU regulator reviews reports of rare nervous disorder after AstraZeneca vaccine

Europe’s medicines regulator said on Friday it was reviewing reports of a rare condition affecting the nerves following vaccination with AstraZeneca’s Covid-19 shot, and requested the British drugmaker for more detailed data.

As part of a regular review of safety reports for the vaccine, Vaxzevria, the European Medicines Agency’s safety committee is analysing data provided on cases of Guillain-Barre syndrome, the regulator said.

AstraZeneca did not immediately respond to requests for comment. [Reuters]

Subscribe to our Newsletters

Enter your information below to receive our weekly newsletters with the latest insights, opinion pieces and current events straight to your inbox.

By signing up you are agreeing to our Terms of Service and Privacy Policy.